CARDIOVASCULAR AGENTS MEDICAL PURPOSES
| Brand | Owner (click to sort) | Address | Description |
|---|---|---|---|
| GWYNTECH | O'Donnell, Edward | 7171 Princeton Ave Saint Louis MO 63130 | Cardiovascular agents for medical purposes;GWYN TECH; |
| INNOPRAN | ANI PHARMACEUTICALS, INC. | 210 Main Street West Baudette MN 56623 | Cardiovascular agents for medical purposes; Cardiovascular pharmaceuticals; Cardiovascular treatment preparations; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for treating hypertension; |
| KINGFLY | XINFULAI (INTERNATIONAL) CO., LIMITED | Room 1508, 15/F., Office Tower Two, Grand Plaza, 625 Nathan Road, Kowloon 999077 China | Cardiovascular agents for medical purposes; Food for babies; Nutritional supplements; Protein dietary supplements;KING FLY; |
| RETAVASE | CHIESI USA, INC. | 175 Regency Woods Place, Ste. 600 Cary NC 27518 | cardiovascular agents for medical purposes, namely, a recombinant plasminogen activator compound for use in the management of acute myocardial infarction; |
Where the owner name is not linked, that owner no longer owns the brand |
Technical Examples
- Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. In addition to reducing or substantially eliminating a biological organism's reaction to the introduction of the medical device to the organism, the medical device in combination with one or more therapeutic drugs, agents and/or compounds may be utilized to treat various vascular diseases, for example, restenosis and vulnerable plaque. In the case of vulnerable plaque, one or more drugs, agents or compounds may be utilized to treat the various aspects of vulnerable plaque and these drugs, agents and/or compounds may be released with a given release profile for the most effective treatment. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.